What is Lexeo Therapeutics Debt-to-Equity?
Lexeo Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.61 Mil. Lexeo Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $8.63 Mil. Lexeo Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $182.95 Mil.
Lexeo Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 0.06.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lexeo Therapeutics's Debt-to-Equity or its related term are showing as below:
LXEO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.12 Med: -0.09 Max: 0.1
Current: 0.06
During the past 4 years, the highest Debt-to-Equity Ratio of Lexeo Therapeutics was 0.10. The lowest was -0.12. And the median was -0.09.
Lexeo Therapeutics Debt-to-Equity Historical Data
The historical data trend for Lexeo Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics Debt-to-Equity Chart
|
Lexeo Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
- |
- |
-0.12 |
0.10 |
|
Lexeo Therapeutics Quarterly Data
|
|
Dec20 |
Dec21 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
N/A |
-0.09 |
-0.10 |
0.10 |
0.06 |
Competitive Comparison of Lexeo Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Lexeo Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexeo Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lexeo Therapeutics's Debt-to-Equity falls into.
Lexeo Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Lexeo Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Lexeo Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics (Lexeo Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Executives
| Lundbeckfond Invest A/s |
10 percent owner |
SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100 |
| Longitude Capital Partners Iv, Llc |
10 percent owner |
2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
| Omega Fund Vi Gp, L.p. |
10 percent owner |
888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
| Omega Fund Vi, L.p. |
10 percent owner |
888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
| Richard Nolan Townsend |
director, officer: Chief Executive Officer |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Jenny Robertson |
officer: Chief Legal and Admin. Officer |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Paul Mccormac |
officer: Chief Technical Officer |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Bernard Davitian |
director |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Eric Adler |
officer: Chief Scientific Officer |
C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
| Brenda Cooperstone |
director |
C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Longitude Venture Partners Iv, L.p. |
10 percent owner |
2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
| Omega Fund Vi Gp Manager, Ltd. |
10 percent owner |
888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
| Paula H Cholmondeley |
director |
221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991 |
| Reinaldo M Diaz |
director |
C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022 |
| Mette Kirstine Agger |
director |
C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830 |
Lexeo Therapeutics (Lexeo Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LXEO has been successfully added to your